FR8142M - - Google Patents

Info

Publication number
FR8142M
FR8142M FR162134A FR162134A FR8142M FR 8142 M FR8142 M FR 8142M FR 162134 A FR162134 A FR 162134A FR 162134 A FR162134 A FR 162134A FR 8142 M FR8142 M FR 8142M
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR162134A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Application granted granted Critical
Publication of FR8142M publication Critical patent/FR8142M/fr
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fastening Of Light Sources Or Lamp Holders (AREA)
FR162134A 1967-08-08 1968-08-07 Expired FR8142M (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB36270/67A GB1242211A (en) 1967-08-08 1967-08-08 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
FR8142M true FR8142M (fr) 1970-08-17

Family

ID=10386572

Family Applications (2)

Application Number Title Priority Date Filing Date
FR162134A Expired FR8142M (fr) 1967-08-08 1968-08-07
FR163601A Expired FR1605538A (fr) 1967-08-08 1968-08-21

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR163601A Expired FR1605538A (fr) 1967-08-08 1968-08-21

Country Status (14)

Country Link
US (1) US3634582A (fr)
JP (1) JPS5643448B1 (fr)
BE (1) BE718846A (fr)
CA (1) CA946280A (fr)
DE (2) DE1792799A1 (fr)
DK (1) DK123276B (fr)
FI (1) FI48973C (fr)
FR (2) FR8142M (fr)
GB (1) GB1242211A (fr)
IE (1) IE32343B1 (fr)
MY (2) MY7400330A (fr)
NL (1) NL161984C (fr)
NO (1) NO128307B (fr)
SE (1) SE372420B (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007855A1 (fr) * 1987-04-09 1988-10-20 Fisons Plc Compositions pharmaceutiques contenant de la pentamidine
US5204113A (en) * 1987-04-09 1993-04-20 Fisons Plc Pharmaceutical compositions containing pentamidine
WO1993011746A1 (fr) * 1991-12-10 1993-06-24 Boehringer Ingelheim Kg Poudres a inhaler et leur procede de fabrication
WO2002030389A1 (fr) * 2000-10-12 2002-04-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Nouvelle poudre a inhaler a teneur en tiotropium
WO2003017970A1 (fr) * 2001-08-23 2003-03-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Procede de saupoudrage pour la production de formulations en poudre
US6585959B2 (en) 2000-10-12 2003-07-01 Boehringer Ingelheim Pharma Kg Process for preparing powder formulations
WO2004047796A3 (fr) * 2002-11-28 2004-09-30 Boehringer Ingelheim Pharma Formulation pulverulente pour inhalation contenant du tiotropium

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1381872A (en) * 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
BE787100A (fr) * 1971-08-06 1973-02-02 Beecham Group Ltd Composition pour le traitement de l'asthme
GB1410588A (en) * 1971-08-10 1975-10-22 Fisons Ltd Composition
DE2332663C2 (de) * 1973-06-23 1986-07-31 Schering AG, 1000 Berlin und 4709 Bergkamen Verwendung von Kortikoid-Wirkstoffen zur Inhalationstherapie
DE2535258C2 (de) * 1974-08-10 1993-06-03 Fisons Plc, Ipswich, Suffolk Inhalierbares Medikament in Pelletform
US4161516A (en) * 1975-07-25 1979-07-17 Fisons Limited Composition for treating airway disease
FI770215A7 (fr) * 1976-01-30 1977-07-31 Fisons Ltd
GB2077100B (en) * 1980-04-30 1985-04-24 Fisons Ltd Pharmaceutical compositions containing cromoglycates
BE891013A (fr) * 1980-11-05 1982-05-05 Fisons Ltd Compositions pharmaceutique
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
DE69330672T2 (de) * 1992-06-12 2002-06-27 Teijin Ltd., Osaka Pharmazeutische zubereitung zur anwendung in den atemwegen
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
IL111080A (en) * 1993-10-01 1999-08-17 Astra Ab Method for treating a finely divided powder medicament
IS1736B (is) 1993-10-01 1999-12-30 Astra Ab Aðferð og tæki sem stuðla að aukinni samloðun agna
NL9301851A (nl) * 1993-10-26 1995-05-16 Cordis Europ Cryo-ablatie catheter.
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9404945D0 (en) 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
US6102036A (en) * 1994-04-12 2000-08-15 Smoke-Stop Breath activated inhaler
US6165976A (en) 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
DE4425255A1 (de) 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
EP0806945B1 (fr) 1994-12-22 2003-04-23 AstraZeneca AB Preparation therapeutique a inhaler contenant de l'hormone parathyroidienne, hpt
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
CN1088580C (zh) 1994-12-22 2002-08-07 阿斯特拉公司 气溶胶药物制剂
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
HU222692B1 (hu) * 1997-05-27 2003-09-29 Direct-Haler A/S Berendezés por alakú vagy szemcsés anyag orrüreg nyálkahártyájára történż juttatására
CZ2001584A3 (cs) * 1998-08-18 2002-06-12 The Regents Of The University Of California Prevence tvorby hlenu v dýchacích cestách podáváním antagonistů EGF-R
US7354894B2 (en) * 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US7207330B1 (en) 1999-06-05 2007-04-24 Innovata Biomed Limited Delivery system
ITMI991582A1 (it) 1999-07-16 2001-01-16 Chiesi Farma Spa Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala
GB9920839D0 (en) 1999-09-04 1999-11-10 Innovata Biomed Ltd Inhaler
EP1129705A1 (fr) * 2000-02-17 2001-09-05 Rijksuniversiteit te Groningen Formulation en poudre pour inhalation
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0009469D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
US20060194773A1 (en) * 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
US8337816B2 (en) * 2001-09-17 2012-12-25 Glaxo Group Limited Dry powder medicament formulations
WO2003043574A2 (fr) * 2001-11-19 2003-05-30 Becton, Dickinson And Company Compositions pharmaceutiques sous forme particulaire
GB0128148D0 (en) 2001-11-23 2002-01-16 Innovata Biomed Ltd Assembly
US6900317B2 (en) 2002-02-19 2005-05-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
US20040014679A1 (en) * 2002-02-20 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co., Kg Inhalation powder containing the CGRP antagonist BIBN4096 and process for the preparation thereof
DE10207026A1 (de) * 2002-02-20 2003-08-28 Boehringer Ingelheim Kg Pulverinhalativum, enthaltend den CGRP-Antagonisten BIBN4096 und Verfahren zu dessen Herstellung
JP2006516531A (ja) * 2002-08-21 2006-07-06 ノートン　ヘルスケアー　リミテッド 吸入組成物
US7763280B2 (en) 2002-11-28 2010-07-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing powder formulation for inhalation
DE10317461A1 (de) 2003-04-16 2004-10-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Radioaktiv markierte Mikropartikel, Verfahren zu deren Herstellung und deren Verwendung
US20050042178A1 (en) * 2003-08-18 2005-02-24 Boehringer Ingelheim International Gmbh Microparticles containing the CGRP-antagonist 1-[N2-[3,5-dibrom-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, process for preparing and the use thereof as inhalation powder
US20050042179A1 (en) * 2003-08-18 2005-02-24 Boehringer Ingelheim International Gmbh Inhalative powder formulations containing the CGRP-antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine
DE10338402A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknetes, amorphes BIBN 4096, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
DE10338407A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Inhalationspulver enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin
DE10338399A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mikropartikel, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazin, Verfahren zu deren Herstellung sowie deren Verwendung als Inhalaltionspulver
DE10338403A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
US20050043247A1 (en) * 2003-08-18 2005-02-24 Boehringer Ingelheim International Gmbh Spray-dried amorphous BIBN 4096, process for preparing and the use thereof as inhalative
DK1699434T3 (da) 2003-09-02 2011-05-30 Norton Healthcare Ltd Fremgangsmåde til fremstilling af et lægemiddel
TW200524577A (en) 2003-11-04 2005-08-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
CA2562386C (fr) 2004-04-21 2014-11-18 Innovata Biomed Limited Inhalateur
GB0409197D0 (en) 2004-04-24 2004-05-26 Innovata Biomed Ltd Device
AR050902A1 (es) 2004-04-27 2006-12-06 Glaxo Group Ltd Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion
US7723306B2 (en) * 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
US7727962B2 (en) * 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
US7611709B2 (en) * 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
DE102004048390A1 (de) * 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pulverinhalativa auf Basis modifizierter Laktosemischungen als Hilfsstoff
DE102004048389A1 (de) * 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Modifizierung von Oberflächen von Laktose als Hilfsstoff zur Verwendung für Pulverinhalativa
JP5156397B2 (ja) * 2005-02-10 2013-03-06 グラクソ グループ リミテッド 予備分級技術を用いて乳糖を製造する方法及びその乳糖から形成させた医薬製剤
EP2307589B1 (fr) 2008-07-24 2018-12-19 L'Air Liquide Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude Méthode pour la déposition de films contenant un métal de transition utilisant précurseurs hétéroleptique de cyclopentadiényle de métal de transition
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
PL3578169T3 (pl) 2009-02-26 2024-09-02 Glaxo Group Limited Preparaty farmaceutyczne zawierające 4-{(1r)-2-[(6-{2-[(2,6-dichlorobenzylo)oksy]etoksy}heksylo)amino]-1-hydroksyetylo}-2-(hydroksymetylo)fenol
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
PT106094A (pt) 2012-01-13 2013-07-15 Hovione Farmaciencia S A Administração por inalação de formulações com dose elevada
US20150165038A1 (en) * 2012-02-10 2015-06-18 Arven llac Sanayi Ve Ticaret A.S. Compositions comprising muscarinic receptor antagonist and sorbitol
US10111957B2 (en) 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
US20150174064A1 (en) * 2012-07-05 2015-06-25 Arven IIac Sanayi Ve Ticaret A.S. Compositions comprising muscarinic receptor antagonist and glucose anhydrous
WO2014007771A2 (fr) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions d'inhalation comprenant un antagoniste du récepteur muscarinique
EP2911664B1 (fr) 2012-10-25 2019-05-08 The General Hospital Corporation Polythérapies pour le traitement de la maladie d'alzheimer et des troubles associés
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
KR102256576B1 (ko) 2013-10-08 2021-05-27 에이아이 테라퓨틱스, 인코포레이티드 림프관평활근종증의 치료를 위한 라파마이신
AU2014340182B2 (en) * 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
PL3125875T3 (pl) 2014-04-04 2023-11-20 AI Therapeutics, Inc. Nadający się do inhalacji preparat rapamycyny do leczenia stanów związanych z wiekiem
AU2015330905B2 (en) 2014-10-07 2021-02-25 AI Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
CA3033079A1 (fr) 2016-08-31 2018-03-08 The General Hospital Corporation Macrophages/microglies dans la neuro-inflammation associee aux maladies neurodegeneratives
IL269275B2 (en) 2017-06-28 2023-04-01 Philip Morris Products Sa Container with particles for use with an inhaler
KR20210070232A (ko) 2017-07-20 2021-06-14 아즈테라피즈 인코포레이티드 크로몰린 나트륨 및 이부프로펜의 분말화된 제형
CA3105392A1 (fr) 2018-07-02 2020-01-09 The General Hospital Corporation Formulations en poudre de cromoglycate de sodium et d'.alpha.-lactose
EP3833964B1 (fr) 2018-08-07 2023-07-26 Norton (Waterford) Limited Application de spectroscopie raman pour la fabrication de poudres à inhaler
EP3893945A4 (fr) 2018-12-10 2022-11-30 The General Hospital Corporation Esters cromoglycique et leurs utilisations
US12458622B2 (en) 2020-04-06 2025-11-04 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
EP4203945A1 (fr) 2020-08-28 2023-07-05 Universität Linz Utilisation de léoligine dans la prévention de lésions tissulaires
WO2026002967A1 (fr) 2024-06-24 2026-01-02 Universität Linz Léoligine et ses dérivés en tant que bloqueurs des canaux calciques pour la prévention et/ou le traitement de maladies associées

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1792207U (de) 1959-04-14 1959-07-16 Esslinger Sack Und Planenfabri Transportables gartenschwimm- oder -planschbecken mit aus kunststoff-folie bestehenden waenden.
FR1489749A (fr) 1965-03-25 1967-07-28 Fisons Pharmaceuticals Ltd Procédé de préparation de composés bis-chromonylés et leurs dérivés

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007855A1 (fr) * 1987-04-09 1988-10-20 Fisons Plc Compositions pharmaceutiques contenant de la pentamidine
US5204113A (en) * 1987-04-09 1993-04-20 Fisons Plc Pharmaceutical compositions containing pentamidine
WO1993011746A1 (fr) * 1991-12-10 1993-06-24 Boehringer Ingelheim Kg Poudres a inhaler et leur procede de fabrication
DE4140689B4 (de) * 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
EP1430887A1 (fr) * 2000-10-12 2004-06-23 Boehringer Ingelheim Pharma GmbH & Co.KG Poudre pour inhalation contenant du tiotropium
US6585959B2 (en) 2000-10-12 2003-07-01 Boehringer Ingelheim Pharma Kg Process for preparing powder formulations
USRE38912E1 (en) * 2000-10-12 2005-12-06 Boehringer Ingelheim Pharma Kg Process for preparing powder formulations
US7070800B2 (en) 2000-10-12 2006-07-04 Boehringer Ingelheim Pharma Kg Inhalable powder containing tiotropium
WO2002030389A1 (fr) * 2000-10-12 2002-04-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Nouvelle poudre a inhaler a teneur en tiotropium
WO2003017970A1 (fr) * 2001-08-23 2003-03-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Procede de saupoudrage pour la production de formulations en poudre
US6905239B2 (en) 2001-08-23 2005-06-14 Boehringer Ingelheim Pharma Kg Sprinkling method for preparing powder formulations
EP1859787A3 (fr) * 2001-08-23 2009-01-14 Boehringer Ingelheim Pharma GmbH & Co. KG Procédé de saupoudrage pour la production de formulations en poudre
WO2004047796A3 (fr) * 2002-11-28 2004-09-30 Boehringer Ingelheim Pharma Formulation pulverulente pour inhalation contenant du tiotropium
EA011549B1 (ru) * 2002-11-28 2009-04-28 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг Новый, содержащий тиотропий порошковый препарат для ингаляции

Also Published As

Publication number Publication date
US3634582A (en) 1972-01-11
FI48973C (fi) 1975-03-10
DE1792207A1 (de) 1971-11-04
NL6811060A (fr) 1969-02-11
DE1792207B2 (de) 1977-10-13
BE718846A (fr) 1969-01-31
SE372420B (fr) 1974-12-23
NL161984B (nl) 1979-11-15
IE32343B1 (en) 1973-06-27
MY7400329A (en) 1974-12-31
MY7400330A (en) 1974-12-31
DK123276B (da) 1972-06-05
IE32343L (en) 1969-02-08
CA946280A (en) 1974-04-30
NL161984C (nl) 1980-04-15
DE1792207C3 (de) 1978-06-29
DE1792799A1 (de) 1977-08-11
NO128307B (fr) 1973-10-29
FR1605538A (fr) 1979-02-23
FI48973B (fr) 1974-12-02
GB1242211A (en) 1971-08-11
JPS5643448B1 (fr) 1981-10-13

Similar Documents

Publication Publication Date Title
FI48973B (fr)
AU5765369A (fr)
AU2277767A (fr)
AU342066A (fr)
AU2116667A (fr)
AU2256867A (fr)
AU3151267A (fr)
AU2977667A (fr)
AU2454867A (fr)
AU3189468A (fr)
AU2528767A (fr)
BE710525A (fr)
BE706549A (fr)
BE711000A (fr)
AU25066A (fr)
BE711013A (fr)
AU2406369A (fr)
AU23366A (fr)
BE710989A (fr)
AU34866A (fr)
BE710471A (fr)
BE709807A (fr)
BE709279A (fr)
BE708879A (fr)
BE708690A (fr)

Legal Events

Date Code Title Description
TP Transmission of property